Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 18, 2006
Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disordersRonald J Mandel, Fredric P Manfredsson, Kevin D Foust, et al.
Brain : a Journal of Neurology|January 22, 2005
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectorsThomas Carlsson, Christian Winkler, Corinna Burger, et al.
Journal of Neurochemistry|August 19, 2009
Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian ratsTomas Björklund, Hélène Hall, Nathalie Breysse, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 30, 2002
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal systemDeniz Kirik, Carl Rosenblad, Corinna Burger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2009
Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumventedCarmen S Peden, Fredric P Manfredsson, Sharon K Reimsnider, et al.
Acta Neuropathologica Communications|June 17, 2017
Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primatesRonald J Mandel, David J Marmion, Deniz Kirik, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 17, 2002
Gene therapy for pyruvate dehydrogenase E1alpha deficiency using recombinant adeno-associated virus 2 (rAAV2) vectorsRenius Owen, Ronald J Mandel, Chandramohan V Ammini, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2008
The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson diseaseOleg S Gorbatyuk, Shoudong Li, Layla F Sullivan, et al.
Brain : a Journal of Neurology|February 17, 2007
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrainAndisheh Eslamboli, Marina Romero-Ramos, Corinna Burger, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 28, 2005
Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's diseaseAndisheh Eslamboli, Biljana Georgievska, Rosalind M Ridley, et al.
Pageof 6